Traversing Key Updates in HR+ and Triple-Negative Breast Cancer

Aditya Bardia, MD, MPH, FASCO, discussed data from the lidERA trial of giredestrant vs SOC endocrine therapy in ER-positive, HER2-negative breast cancer.

Komal Jhaveri, MD, FACP, discusses lessons learned from the negative phase 3 ASCENT-07 trial in hormone receptor–positive, HER2-negative breast cancer.

The INAVO123 trial is exploring frontline inavolisib plus a CDK4/6 inhibitor and letrozole in PIK3CA-mutant, hormone receptor–positive breast cancer.

Hope S. Rugo, MD, highlights emerging research with targeted therapies and oral SERDs that may influence the HR-positive breast cancer treatment paradigm.

Kevin Kalinsky, MD, MS, FASCO, discusses clinical data potentially supporting the use of TROP2-directed ADCs in frontline metastatic TNBC.

Sara M. Tolaney, MD, MPH, discusses updated safety data from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in PD-L1–positive TNBC.

Safety analysis shows sacituzumab govitecan plus pembrolizumab has a manageable profile and fewer dose reductions than chemoimmunotherapy in PD-L1+ TNBC.

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

Sacituzumab govitecan did not improve PFS per BICR vs chemotherapy after endocrine therapy in hormone-receptor–positive/HER2-negative breast cancer.

Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.